Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Open-label, single centre study evaluating efficacy and viral kinetics of combination
PEG-IFNa2a and Ribavirin treatment on CHC genotype 1 patients, administered until viral
clearance demonstrated between 4 - 12 weeks, then randomised to further continued combination
treatment for one of three defined durations. Followed-up for 24 weeks after treatment
cessation.
Objectives:
1. To determine the necessary duration of combination treatment with Pegylated-Interferon
alfa2a (PEGASYS) & Ribavirin in Patients infected with genotype 1, in order to achieve
viral clearance
2. To identify host factors, which are associated with different patterns of virological
response to combination treatment (fast responder, slow responder, non-responder). On
this basis, to identify possible predictors for the duration of antiviral treatment.